A Oregon overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
33.5% of Oregon adults had obesity in 2024, per CDC BRFSS state prevalence data 1 — up from 29.0% in 2019, a 4.5-point rise across five years in the same series 1.
The Oregon Health Plan moved in a different direction over the same stretch: its weight-management criteria were most recently reviewed in February 2026 and implemented March 1, 2026, and they say plainly that drugs prescribed for weight management alone are not covered 3.
Not for weight management by itself. Under the Drug Use Research & Management Program's "Weight Management Drugs" prior-authorization criteria — reviewed February 2026, implemented March 1, 2026 — the Oregon Health Plan carves coverage out narrowly by diagnosis, not by weight 3. The criteria state that "drugs prescribed for only weight management (overweight or obesity) are NOT currently covered" 3.
The doors that are open are diagnosis-specific. Semaglutide (Wegovy) is covered only for established cardiovascular disease or for MASH — metabolic dysfunction-associated steatohepatitis, stage 2-3 fibrosis. Tirzepatide (Zepbound) is covered only for moderate-to-severe obstructive sleep apnea (AHI ≥15) in a patient who also has obesity (BMI ≥30). Liraglutide (Saxenda) is covered only for MASH 34. A separate pathway covers semaglutide (Ozempic/Rybelsus) and tirzepatide (Mounjaro) for type 2 diabetes, and that route does not extend to weight-loss-only prescribing 3.
This is fee-for-service policy 34. Most OHP members are enrolled in Coordinated Care Organizations, which must fund at least what the HERC Prioritized List covers and generally mirror this carve-out 56 — though individual CCO formularies were not checked line by line for this page, so read the CCO hedge as a hedge, not as a blanket "Medicaid never covers this" claim.
Astra's price in Oregon is the price everywhere else we operate: $68 a month for compounded semaglutide and $118 a month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416, the same at every dose. There is no Oregon price list, no regional surcharge, and no local discount.
An estimated 5.2% of Oregonians had no health insurance and median household income was $85,220, per the Census Bureau's 2020–2024 ACS 5-year estimates 8. For the Oregonians who fall outside all three of OHP's diagnosis carve-outs, a published flat price is the number that actually applies.
Oregon has 153 federally designated Primary Care Health Professional Shortage Areas, 97 of them flagged rural, per HRSA's live shortage-area designations checked August 28, 2026 7. That is a rural-access gap outside the Portland metro, and it is the gap telehealth is built to close: intake, prescribing, and follow-up happen without a drive to a clinic in another county.
The licensing authority for the physicians who would treat an Oregon patient is the Oregon Medical Board. TODO — internal flag, not yet resolved: current OMB telehealth prescribing rules (real-time audio-video standard, established-patient-relationship requirement, any GLP-1-specific guidance) have not been independently checked against omb.oregon.gov this research pass. We are not asserting a specific Oregon rule until someone reads the current rule text.
Astra serves patients in all 50 states, Oregon included. Care starts online, there is no in-state clinic visit required, and the price does not change based on where in Oregon a patient lives.
Astra treats patients in Oregon through state-licensed physicians.
Eugene and Salem have their own pages, with city-level data and local access detail under the same sourcing rules as this page.
No — not for weight loss alone. OHP's Weight Management Drugs policy (implemented Mar. 1, 2026) covers semaglutide only for established cardiovascular disease or MASH, and tirzepatide (Zepbound) only for moderate-to-severe obstructive sleep apnea in a patient who also has obesity. There is no OHP pathway that covers a GLP-1 for obesity or overweight by itself.
No. Astra's prices are national: $68/mo for semaglutide and $118/mo for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). The price is identical whether you're in Portland, Eugene, Salem, or any other U.S. city — Oregon gets no markup and no discount.
33.5% of Oregon adults had obesity as of the CDC's 2024 BRFSS survey — up from 29.0% just five years earlier, one of the faster five-year increases among states with comparable data.
Yes — that's the specific gap telehealth is built to close. Oregon has 153 federally designated primary-care shortage areas, 97 of them rural, so patients outside the Portland metro often face longer drives or waits for an in-person specialist. Astra's clinicians see patients by video appointment statewide, including in Eugene and Salem.
Yes. Astra is licensed to treat patients in all 50 states, including Oregon.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.